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Background: Parkinson’s disease (PD) is characterized by reduced flexibility, conceptual-
ization, and visuo-spatial abilities. Although these are essential to creativity, case studies
show emergence of creativity during PD. Knowledge about the role of dopamine in creativ-
ity so far only stems from a few case reports. We aim at demonstrating that creativity can
be induced by dopaminergic treatments in PD, and tends to disappear after withdrawal of
dopamine agonists.
Methods: Eleven consecutive creative PD patients were selected from candidates for
subthalamic nucleus deep brain stimulation (STN DBS) surgery, and compared to 22 non-
creative control PD patients. Motor disability (UPDRS III), cognition (Frontal score, Mattis
scale), and behavior (Ardouin scale) were assessed before surgery and 1 year after.
Results: Before surgery, whereas cognitive and motor assessments were similar between
groups, dopamine agonist (but not levodopa) dosages were higher in creative patients
(p=0.01). The Ardouin scale revealed also a specific psycho-behavioral profile of creative
patients which had higher scores for mania (p<0.001), hobbyism (p=0.001), nocturnal
hyperactivity (p=0.041), appetitive functioning (p=0.003), and ON euphoria (p=0.007)
and lower scores for apathy and OFF dysphoria (p=0.04 for each). Post-operative motor,
cognitive, and behavioral scores as dopaminergic treatment dosages were equivalent
between groups. Motor improvement allowed for a 68.6% decrease in dopaminergic treat-
ment. Only 1 of the 11 patients remained creative after surgery. Reduction of dopamine
agonist was significantly correlated to the decrease in creativity in the whole population
of study (Spearman correlation coefficient ρ=0.47 with confidence index of 95%=0.16;
0.70, p=0.0053).
Conclusion: Creativity in PD is linked to dopamine agonist therapy, and tends to disappear
after STN DBS in parallel to reduction of dopamine agonists, which are relatively selective
for the mesolimbic D3 dopamine receptors.
Keywords: STN DBS, impulse control disorders, creativity, dopamine, Parkinson’s disease
INTRODUCTION
For a production to qualify as “creative,” it must fulfill two criteria:
it must be new (or original) and useful (or valuable, or relevant)
(1). However, this both criterions are subjective. A creative work
is not the result of a single cognitive process, of neuronal activ-
ity in one isolated cerebral area, or of a unique mental faculty,
but of the interaction of multiple cognitive processes supported
by a large network of multiple cerebral areas. The neurotransmit-
ter dopamine plays a crucial role in this complex interaction. A
link seems to exist between mental illness, notably bipolar dis-
order, dopamine, and creativity. Many well-known artists (e.g.,
Edward Munch, Ernest Hemingway, and Virginia Woolf) suf-
fered from bipolar disorder and 38.3% of British artists who
received awards were treated for affective disorders (2). A strong
dopaminergic component is reported in bipolar disorder, treated
by antidopaminergic medication. Many artists admit to being
more creative under the influence of psychoactive or “psychedelic”
drugs. Drugs that can lead to addiction induce a large release
of dopamine in the mesolimbic pathway, directly for ampheta-
mine and cocaine by blocking dopamine reuptake, and indirectly
for other psychoactive drugs such as alcohol (3). The dopamin-
ergic mesolimbic pathway is involved in the control of moti-
vational, reward, and reinforcement processes and contributes
to dependence and addiction. Eysenck proposed that people in
whom the “psychoticism” personality trait is strong, experience
a “widening of the associative horizon,” which could generate
creativity by weakening latent inhibition of thought (4). He also
reported a link between psychoticism, which is highly represented
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in mental illness and increased dopamine levels. Flaherty proposed
a tridimensional model of creativity, in which frontal, temporal,
and dopaminergic systems modulate idea generation and cre-
ativity, influenced by medical conditions and treatments (5, 6).
Two recent neurobiological studies established a link between
dopamine and creativity (7, 8). In Parkinson’s disease (PD), (i)
depletion of the substantia nigra and the ventral tegmental area
causes low dopamine concentration in the brain and (ii) cognitive
impairment diminishes flexibility processes essential to creativity.
To Lakke’s surprise, artistic activity persisted in PD, and in the
case of several patients was awakened, from the time of disease
onset (9). Many case reports confirm exacerbation or revelation
of creative art work in PD patients treated by dopamine replace-
ment therapy (DRT) and especially dopamine agonists (10–13).
Very thoughtfully and exhaustive reviews sustain strongly the link
between dopaminergic treatment and awakening of creativity in
PD, but to date, there is only case report and no group study
permitting to support this assertion (6, 14). Deep brain stimu-
lation (DBS) of the subthalamic nucleus (STN) allows reduction
of DRT by 50% on average, maintaining a stable and relatively
good motor state (15). STN stimulation in PD allows longitudi-
nal monitoring of the consequences of dopamine modulation on
creativity and other motivational behaviors (16). DBS targets the
sensorimotor part of the STN, which depends on the nigrostri-
atal dopaminergic pathway. The limbic part of the STN, which
depends on the mesolimbic dopaminergic pathway, is less influ-
enced by DBS. STN DBS thus can indirectly unmask non-motor
symptoms related to lesions in the mesolimbic dopaminergic sys-
tem (17). We conducted a case controlled comparative study in
PD patients undergoing STN DBS surgery to assess the influ-
ence of DRT on creativity. By comparing psychological features in
creative and non-creative patients, we aimed to describe the poten-
tial individual co-variables of creativity, particularly hypomanic
mood and impulse control disorders, which are also modulated
by DRT.
MATERIALS AND METHODS
STUDY POPULATION AND DESIGN
A total of 76 consecutive patients underwent bilateral STN DBS
in Grenoble between December 2004 and August 2007. Selection
criteria for surgery were: (i) clinically diagnosed PD; (ii) severe l-
DOPA-related motor complications despite optimal adjustment
of anti-Parkinsonian medication; (iii) age under 70 years; and
(iv) absence of surgical contraindications, dementia, or major on-
going psychiatric illness (18). Eleven patients fulfilled the study’s
specific inclusion criteria, i.e., had a score ≥2 for the “creativity”
item of the Ardouin scale (16, 19). For each identified creative
case, two PD controls with no significant creative behavior (“cre-
ativity”≤1 on the Ardouin scale) were selected. These PD controls
had undergone STN DBS surgery immediately before and imme-
diately after the identified case. The sample’s characteristics are
described in Table 1. Assessments took place in the month preced-
ing surgery and 1 year (±1 month) later. Exhaustive evaluations
of mood, behavior, and cognition were carried out during routine
hospital visits by a clinical neuropsychologist experienced in the
assessment of neuropsychiatric symptoms in PD. All evaluations
were conducted prospectively; data collection was retrospective.
We added a case report to illustrate the changes in creative behavior
related to dopamine agonist modifications.
OUTCOME MEASURES
Motor outcome and treatment
Dopaminergic treatment was expressed in (i) daily dopamine ago-
nist equivalent dose, (ii) daily l-DOPA dose, and (iii) total daily
dopamine equivalent dose. Dopamine agonist equivalent dose was
calculated by comparison to 100 mg l-DOPA in terms of motor
anti-Parkinsonian effect (18). Total daily dopamine equivalent
dose is the sum of dopamine agonist equivalent and l-DOPA
doses. Psychotropic medication (atypical neuroleptic, antidepres-
sant, benzodiazepine, sleeping pills) was noted. Chronic stimu-
lation parameters were noted at post-operative follow-up. The
Unified Parkinson’s Disease Rating Scale part III (motor score)
was used to assess the beneficial effects of l-DOPA and subthala-
mic stimulation on Parkinsonian motor signs (20). Before surgery,
UPDRS III was evaluated in OFF and ON medication conditions
using suprathreshold doses of l-DOPA (18). This assessment was
repeated at follow-up, in four treatment conditions (OFF med-
ication/ON stimulation; OFF medication/OFF stimulation; ON
medication/OFF stimulation; ON medication/ON stimulation).
Cognitive evaluation
Overall cognitive function was assessed using the Mattis dementia
rating scale (21). The degree of frontal–subcortical deterioration
was evaluated using the frontal score, a more specific test battery
measuring frontal executive function (22). Assessment included
the simplified version of the Wisconsin Card Sorting Test (23),
verbal fluency tests (24), and graphic and motor series (25).
Evaluation of mood and behavior
Ardouin scale. This previously described instrument (19) is
currently undergoing validation in PD (Rieu et al., submitted).
Patients’ general psychological state is assessed (depressive, hypo-
manic or manic mood, anxiety, irritability, hyper-emotivity, and
psychotic symptomatology),as are apathy,non-motor fluctuations
(non-motor ON and non-motor OFF), and hyperdopaminergic
behaviors (12 items: nocturnal hyperactivity, diurnal somno-
lence, excessive eating, creativity, hobbyism, punding, risk-seeking
behavior, compulsive shopping, pathological gambling, hyper-
sexuality, compulsive dopaminergic medication use, and overall
functioning in an appetitive mode). The frequency and intensity
of a symptom’s occurrence in the preceding month is rated on a
scale ranging from 0 (absent) to 4 (severe). A score of 0 indicates
no modification of the patient’s usual habits; a score of 1 reflects
slight modification; a score of 2 is indicative of a moderate mod-
ification in habitual behavior that is usually significant enough
to require therapeutic adjustment; and a score >2 equates with
clear-cut maladaptive pathological behavior requiring immediate
therapeutic intervention. All 11 creative patients scored≥2 on the
“creativity” item, and had experienced a recent emergence of or
increase in creative activity, accompanied by an addictive driving-
force (e.g., individuals pursued the creative activity for longer than
initially intended, especially at night; their daily activity revolved
around creativity, and considerable time was devoted to it; other
behavioral repertoires, such as meals, social, occupational, and
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Table 1 | Patients’ characteristics before and 1 year after surgery, expressed by median (25th; 75th percentile).
Before surgery 1 year after surgery
Creative group
(n=11)
Control group
(n=22)
p Creative group
(n=11)
Control group
(n=22)
p
GENERAL CHARACTERISTICS
Sex (% of female) 45.5% 31.8% 0.443 – –
Age (years) 53 (51; 57) 56.5 (52; 63) 0.358 – –
Disease duration (years) 11 (9; 12) 11 (9; 14) 0.758 – –
Hemi body onset of PD (% of L/R/Bilat.) (45/50/5) (55/45/0)
DRT treatment duration (years) 10 (7; 12) 9.5 (7; 13) 0.673 – –
Education (years) 12 (9; 17) 9 (9; 14) 0.160 – –
DRT
Dopamine agonist equivalent dose (mg/day) 400 (350; 500) 300 (180; 320) 0.012 120 (0; 210) 37.5 (0; 400) 0.952
L-DOPA (mg/day) 885 (450; 1170) 1070 (845; 1320) 0.181 100 (0; 300) 75 (0; 325) 0.830
Total dopamine equivalent dose (mg/day) 1980 (1400; 2760) 2440 (1920; 2950) 0.359 300 (150; 900) 575 (150; 900) 0.970
MOTOR OUTCOME
UPDRS III ON medication /108 9.5 (8; 12) 8.5 (5; 10.5) 0.130 8 (5; 17.5) 10.8 (6.5; 18) 0.359
UPDRS III OFF medication /108 36 (33; 41) 36 (28; 43) 0.909 11 (8; 28) 15.5 (11.5; 25) 0.422
COGNITIVE OUTCOME
Mattis dementia rating scale /144 141 (140; 143) 137.5 (132; 140) 0.018 141 (138; 142) 136.5 (130; 140) 0.043
Attention /37 36 (35; 37) 35.5 (35; 36) 0.303 36 (35; 37) 35.5 (35; 36) 0.440
Initiation /37 37 (37; 37) 35.5 (34; 37) 0.022 37 (35; 37) 33.5 (29; 37) 0.022
Construction /6 6 (6; 6) 6 (6; 6) 0.480 6 (6; 6) 6 (6; 6) 1.000
Conceptualization /39 38 (36; 39) 37 (36; 38) 0.329 39 (38; 39) 37.5 (34; 39) 0.077
Memory /25 24 (24; 25) 24 (22; 25) 0.443 24 (23; 25) 25 (23; 25) 0.566
Frontal score /50 41.9 (41; 46.6) 37.3 (29.5; 43.5) 0.136 41.8 (40.3; 44.7) 39.5 (29.8; 45) 0.340
Wisconsin Card Sorting Test /20 15 (15; 20) 12 (9; 18) 0.085 18 (15; 20) 16.5 (9; 18) 0.082
Verbal fluency /10 8.6 (7.7; 10) 8.3 (7; 10) 0.493 6.7 (6.3; 8.3) 7 (5.3; 9) 0.939
Motor series /10 10 (9.2; 10) 9.3 (6.1; 10) 0.076 8.6 (7.4; 10) 9.3 (6.8; 10) 0.937
Graphic series /10 7 (6.2; 10) 7 (5; 10) 0.433 10 (6.2; 10) 8.8 (5; 10) 0.434
APATHY AND DEPRESSION
Beck depression inventory /63 6 (1; 8) 10 (8; 17) 0.002 8 (6; 9) 6.5 (3; 11) 0.455
Starkstein apathy scale /42 5 (2; 7) 8.5 (5; 12) 0.021 10 (7; 13) 14 (10; 17) 0.283
After surgery, evaluations are made under chronic stimulation parameters.
recreational activities were abandoned in favor of the creative
activity, as were family or professional obligations).
Beck depression inventory II. The Beck depression inventory
(BDI), a self-reported scale validated in PD, was used to determine
the severity of depressive symptoms (26, 27).
Starkstein apathy scale. Since a lack of motivation is often
observed in the post-operative year following STN DBS (17), and
probably influences the desire to engage in creative activity, the
Starkstein apathy scale was used to measure motivation (28, 29).
Statistical analyses
Categorical parameters were summarized in terms of size and fre-
quency, and continuous parameters by median and 25th; 75th
percentiles. A Mann–Whitney test was performed on all para-
meters, in creative and control groups before surgery and 1 year
after surgery. A Wilcoxon test was used to compare each of
the all variables before surgery and 1 year after, in both groups.
Independence between qualitative parameters was assessed using
the chi-square test. A non-parametric Spearman test was com-
pleted to evaluate rank correlation coefficient. p-Values <0.05
were considered statistically significant. Statistical analyses were
performed using STATA release 12 (StataCorp, College Station,
TX, USA) PC-software.
RESULTS
The general characteristics of the patients are shown in Table 1.
In creative patients, artistic work either started when taking
DRT (n= 6) or pre-existing creativity was markedly exacerbated
after the introduction of DRT (n= 5). Art work consisted of
sculpting (n= 1), face casting (n= 1), painting (n= 3), glass
painting (n= 1), drawing (n= 1), graphic design (n= 1), and
writing (poetry n= 1, history book n= 1, short stories n= 1).
Two patients in the control group had a “creativity” item score= 1,
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indicating a slight recent emergence or exacerbation of creative
activity.
While creative and control patients’ total DRT dosages were
the same, creative patients’ dopamine agonist equivalent doses
were higher than controls’ at baseline (Table 1). Motor improve-
ment permitted post-operative reduction in dopamine agonist
equivalent and total DRT equivalent doses to the same extent in
both groups, i.e., by 68.6% on average: l-DOPA daily dose was
reduced from 885 to 100 mg/day (p= 0.008) in the creative group
and from 1070 to 75 mg/day in the control group (p≤ 0.001); sim-
ilarly, daily dopamine agonist equivalent dose was reduced from
400 to 120 mg/day in the creative group (p= 0.014) and from
300 to 37.5 mg/day in the control group (p= 0.240). Reduction
of dopamine agonist was significantly correlated to reduction of
creativity in the whole population of study [Spearman correlation
coefficient ρ= 0.47 with confidence index of 95%= 0.16; 0.70,
p= 0.0053].
Eleven patients in the creative group were taking dopamine
agonists at preoperative assessment, 6/11 were treated by ropini-
role, 3/11 by piribedil, 1/11 by pramipexole, and 1/11 by pergolide.
One patient in the creative group was taking amantadine. Eigh-
teen of 22 patients in the control group were taking dopamine
agonists at preoperative assessment, 4/22 were treated by ropini-
role, 5/22 by piribedil, 3/22 by pramipexole, and 6/22 by per-
golide. Five patients in the control group were taking amantadine.
Thirty-three patients were treated by l-DOPA before surgery. At
post-operative assessment, 7/11 creative patients were treated by
l-DOPA, and 14/22 control patients. Seven of 11 creative patients
were treated by dopamine agonists (3/7 ropinirole, 2/7 piribedil,
and 2/7 pramipexole) vs. 10/22 control patients (1/10 ropinirole,
8/10 piribedil, 1/10 bromocriptine). Median dosages are presented
in Table 1. Stimulation parameters did not differ between groups
and were similar for both hemispheres, with a mean (±SD) stim-
ulation strength of 2.9± 0.4 V in creative patients vs. 3.1± 0.4 in
control patients, a median (25th–75th) frequency of 130 (130–
145) Hz in the creative group vs. 130 (130–145) in the control
group, and a median (25th–75th) pulse duration of 60 (60–60)
µs in the creative group vs. 60 (60–75) in the control group. In
each group, one patient was on clozapine, an atypical neurolep-
tic (Table 2). Creative patients were more frequently treated by
antidepressants and benzodiazepines than control patients from
baseline (Table 2). The small sample size does not, however, permit
statistical analysis.
Table 2 | Psychotropic sedative drugs.
Before surgery 1Year after surgery
Creative patients (n=11) Neuroleptic: n=1 Neuroleptic: n=1
Antidepressant: n=4 Antidepressant: n=3
Benzodiazepine: n=4 Benzodiazepine: n=4
Soporific: n=0 Soporific: n=0
Control patients (n=22) Neuroleptic: n=1 Neuroleptic: n=1
Antidepressant: n=1 Antidepressant: n=2
Benzodiazepine: n=0 Benzodiazepine: n=2
Soporific: n=2 Soporific: n=0
At preoperative and post-operative assessments, ON and OFF
medication conditions for UPDRS motor scores did not differ
between groups (Table 1). Post-operative improvement in UPDRS
motor score in off drug on stimulation condition was superior by
50% on average.
Overall cognitive function performance was better in creative
patients than in controls, with higher scores in the “initiation”
subscale of the Mattis dementia rating scale, which measures verbal
fluency and graphic automatisms (Table 1). There was no differ-
ence in executive function scores in the two groups. Verbal fluency
decreased in all patients following surgery: median scores went
from 8.6/10 to 6.7/10 in creative patients (p= 0.029) and from
8.3/10 to 7/10 in control patients (p= 0.003).
Before surgery, creative patients exhibited a specific pattern
of hyperdopaminergic behaviors at the Ardouin scale (Table 3):
they were more hypomanic, more active at night, had higher
scores on “hobbyism,” and functioned in a more markedly appet-
itive mode than control patients. They were less apathetic. They
had more pronounced non-motor ONs phases (they experienced
greater artificial euphoria during ON phases), and less severe
non-motor OFFs phases (they were less dysphoric, anxious, tired
during OFF phases). One year after surgery, overall differences
between creative and control patients had diminished: creativ-
ity and appetitive functioning were still more highly represented
in the creative group, but there were no longer any differences
in the other variables. One year after surgery, following the
reduction in dopaminergic treatment, creative patients were less
hypomanic (p= 0.004), more apathetic (p= 0.016), non-motor
ON had diminished (p= 0.003) as had nocturnal hyperactiv-
ity (p= 0.015), creativity (p= 0.002), hobbyism (p= 0.004), and
appetitive functioning (p= 0.003). Hyperdopaminergic behav-
iors also diminished in control patients. One year after surgery,
clinically relevant creative behavior persisted in only 1 of the 11
patients.
Before surgery, creative patients had lower scores for depressive
mood than control patients (p= 0.002) at the BDI. After surgery,
there was no difference between groups. Before surgery, creative
patients were less apathetic than control patients (p= 0.021). After
surgery, apathy scores increased in both groups: from 5 to 10 in
creative patients (p= 0.003) and from 8.5 to 14 in control patients
(p= 0.049) (Table 1).
CASE REPORT
The case of this woman illustrates the influence of dopamine ago-
nists on creativity. PD started in 1994, at age 41, with pain in
the right arm. She developed a depressive syndrome on learning
the PD diagnosis. A few years later, on a high dose of pramipex-
ole (2.8 mg/day) associated with levodopa (daily equivalent dose
of levodopa= 1100 mg/day), she experienced strong exacerbation
of her painting activity (Figure 1), accompanied by nocturnal
hyperactivity and psychosis. Dopaminergic addiction followed,
as did an escalation to painting addiction (Figures 2–4), asso-
ciated with compulsive buying of painting material and risk-
taking behavior. Her life-style changed completely, and her home
became a gathering place where her artist friends met up and
partied. All the behavioral modifications she experienced had
major repercussions, upsetting her personal, family, and social
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Table 3 | Ardouin scale scores expressed by median (25th; 75th percentile) before and 1 year after surgery.
Before surgery 1 year after surgery
Creative group
(n=11)
Control group
(n=22)
p Creative group
(n=11)
Control group
(n=22)
p
GENERAL PSYCHOLOGICAL STATE
Depressive mood 0 (0; 1) 0 (0; 1) 0.883 0 (0; 1) 0 (0; 1) 0.795
Hypomanic or manic mood 1 (1; 2) 0 (0; 0) ≤0.001 0 (0; 0) 0 (0; 0) 1.000
Anxiety 0 (0; 1) 0 (0; 1) 0.810 0 (0; 0) 0 (0; 1) 0.136
Irritability 0 (0; 1) 0 (0; 1) 0.760 0 (0; 1) 0 (0; 0) 0.647
Hyper-emotivity 0 (0; 1) 1 (0; 2) 0.196 0 (0; 0) 0.5 (0; 1) 0.057
Psychotic symptomatology 0 (0; 0) 0 (0; 1) 0.373 0 (0; 0) 0 (0; 0) 0.437
OVERAL FUNCTIONING IN APATHETIC MODE
Apathy 0 (0; 0) 0 (0; 1) 0.040 1 (0; 2) 0.5 (0; 2) 0.759
NON-MOTOR FLUCTUATIONS
Non-motor ON 2 (2; 3) 1 (0; 2) 0.007 0 (0; 0) 0 (0; 0) 0.310
Non-motor OFF 0 (0; 2) 1 (1; 3) 0.040 0 (0; 0) 0 (0; 1) 0.185
HYPERDOPAMINERGIC BEHAVIOURS
Nocturnal hyperactivity 1 (0; 3) 0 (0; 0) 0.041 0 (0; 0) 0 (0; 0) 0.480
Diurnal somnolence 0 (0; 1) 0.5 (0; 1) 0.558 0 (0; 0) 0 (0; 1) 0.463
Excessive eating behaviour 1 (0; 1) 0 (0; 2) 0.228 1 (1; 2) 0 (0; 1) 0.008
Creativity 2 (2; 3) 0 (0; 0) ≤0.001 0 (0; 1) 0 (0; 0) 0.003
Hobbyism 3 (1; 3) 0 (0; 1) 0.001 0 (0; 0) 0 (0; 0) 0.157
Punding 0 (0; 0) 0 (0; 0) 0.611 0 (0; 0) 0 (0; 0) 1
Risk-seeking behaviour 0 (0; 1) 0 (0; 0) 0.538 0 (0; 1) 0 (0; 0) 0.012
Compulsive shopping 0 (0; 1) 0 (0; 0) 0.574 0 (0; 0) 0 (0; 0) 0.480
Pathological gambling 0 (0; 0) 0 (0; 0) 0.206 0 (0; 0) 0 (0; 0) 0.480
Hypersexuality 0 (0; 1) 0 (0; 1) 0.653 0 (0; 0) 0 (0; 0) 0.206
Compulsive dopaminergic medication use 1 (0; 2) 0 (0; 2) 0.493 0 (0; 0) 0 (0; 0) 0.710
Overall functioning in an appetitive mode 2 (2; 3) 1 (0; 1) 0.003 0 (0; 1) 0 (0; 0) 0.005
FIGURE 1 |Three works from her first, non-addictive period.
equilibrium, and led to hospitalization, reduction in dopamin-
ergic treatment, and the introduction of clozapine. A subsequent
increase in akinesia required higher doses of levodopa, which in
turn induced the onset of motor complications. As a result, STN
DBS surgery was performed in 2009. Neurosurgical treatment led
to improvement in motor fluctuations and reduction of dopamin-
ergic therapy. Her creative activity remained rich, and was judged
by the patient herself to be more tranquil and satisfying. She mostly
sculpts now (Figure 5). She did not dare to pick up a paintbrush
for a long time. She was afraid of falling prey to the devastat-
ing addiction to painting again. Here is her own account: I’ve
always drawn and painted. As an adolescent, I would paint on
the walls of my attic. But in 2002, I embraced painting totally
(Figure 1). I transformed my home into a studio, with tables and
canvases everywhere. I was so happy. My illness got worse in 2004:
I stopped working and went on new medication. At that point, I
started painting from morning till night, and often all through the
night until morning. I was obsessed with painting. I bought huge
amounts of materials, and used countless numbers of brushes at
a time. I used knives, forks, sponges . . . I would gouge open tubes
of paint – it was everywhere (Figure 2) . . . But I was still in con-
trol at that point. Then, the urge to paint became incontrollable.
I started painting on the walls, the furniture, even the washing
machine (Figure 3). I would paint any surface I came across. I also
had my “expression wall” and I could not stop myself from paint-
ing and repainting this wall every night in a trance-like state. My
uncontrollable creativity had turned into something destructive
(Figure 4). My partner could no longer bear it. People close to me
realized that I crossed some kind of line into the pathological, and
in 2006, at their instigation, I was hospitalized. Today, my doctors
have succeeded in getting my medication under control, and my
creativity has become more tranquil and structured. It has once
again become a pleasure, which upsets no-one (Figure 5) (30).
Works illustrating the periods of the patient’s creativity are
reproduced with her authorization (Figures 1–5).
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FIGURE 2 | Addictive period. Painting of romantic relationships illustrating the change in content and technique.
DISCUSSION
FREQUENCY OF CREATIVITY
Our study revealed a high prevalence of creativity (14.5%). This
contrasts with the small number of cases reported in the litera-
ture to date. The scale used probably enabled easier detection of
creativity than do patients’ spontaneous accounts of this aspect
of their lives, as it systematically evaluates all modifications in
behavior. Moreover, surgical candidates are, typically, young, have
long disease and treatment durations, and severe motor symptoms
justifying high doses of DRT including dopamine agonists which
are not recommended for the elderly (31). Hyperdopaminergic
behavioral modifications are frequently and commonly observed
in this Parkinsonian sub-population. In another, larger cohort,
prevalence of creativity was quite similar (16).
CREATIVITY AND PUNDING
Punding is a frequent behavioral modification in PD, in which
prevalence ranges from 0.3 to 14% and is associated with
dopaminergic medications and impulse control disorder (32).
Punding describes a heterogeneous set of aimless, stereotyped
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FIGURE 3 | Addictive period. Examples of furniture and equipment being transformed in pieces of art illustrating the change in quantity and in surfaces of
application.
behaviors performed for long periods of time at the expense of
other activities (33). To our point of view, creativity is the opposite
of punding in its fundamental characteristics: by definition, cre-
ativity implies: (i) novelty, not repetitiveness and (ii) usefulness,
not aimlessness. In fact, punding is even discussed to be included
in the rubric of stereotypies (34).
LINK BETWEEN CREATIVITY AND DOPAMINE AGONISTS
Reduction of creativity was correlated with decrease in dopamine
agonists’ drugs. Creative patients took higher doses of dopamine
agonists than control patients before surgery. Both groups were,
however, similar in terms of severity of motor symptomatology,
and stage of disease. It seems that, as has been demonstrated
for other behavioral modifications, dopaminergic agonists play
a crucial role in the occurrence of addictive appetence to pleasure,
whether it concerns creative behavior, gambling, shopping, eating,
or sexual activity (35). Obviously, creativity belongs to activities
driven by the reward system.
Because of their high affinity with D3 receptors which are
mainly expressed in the mesolimbic pathway, like psychedelic
drugs, currently available D2–D3 dopamine agonists may facil-
itate creative ideas and their expression. It seems plausible that
dopamine agonists encourage greater freedom of association and
artistic production.
Artists such as Jack Kerouac, Jean-Paul Sartre, Johnny Cash,
or Andy Wharhol, who all used amphetamines to facilitate cre-
ative inspiration in their specific artistic domains can be cited
to illustrate our point of view. Jack Kerouac typed his best-seller
“On the road” in 3 weeks, working day and night, on a continu-
ous roll of paper, chosen to avoid interrupting his rhythm, in a
creative “trance” that he could not bear to break by changing the
paper in his typewriter. Amphetamines induce an acute increase
in dopamine in the accumbens shell (36), which expresses the
D3 receptor (37). While pharmacological, neuro-anatomical, and
genetic data suggest a crucial role of the D3 receptor in pharmaco-
dependence (38), it would also be interesting to study its implica-
tion in behavioral addictions which seem to have a mechanism in
common with drug addiction (16).
Dopamine agonists can induce hallucinations in which sta-
tic objects change into moving or living objects. They are
therefore likely to alter perception and perhaps facilitate visual
inspiration (39).
Moreover, by acting on the nucleus accumbens, one of the main
components of cerebral reward circuits (40), dopamine agonists
probably encourage positive feedback on the creative artist’s own
work, which makes presenting his/her work to others easier due
to increased self-confidence, audacity, and non-conformism. This
is compatible with the individual psychological predispositions
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FIGURE 4 | Addictive period. The painting bears the inscription “Am I going nuts?” illustrating maintenance of self-criticism by the patient.
FIGURE 5 | Resumption of a calm and satisfying creativity.
of our creative patients, who were indeed more hypomanic than
control patients.
Finally, mesolimbic denervation leads, via compensatory mech-
anisms, to increased sensitivity to the psychostimulant effects of
dopaminergic treatment, as has been shown in the animal model
of dopaminergic lesions treated with dopaminergic drugs (41, 42).
This is analogous with the higher propensity of PD patients with
more severe nigrostriatal denervation to develop dyskinesia (43).
CREATIVITY REVERSAL AFTER REDUCTION OF DOPAMINERGIC
THERAPY
We demonstrated indirectly that creativity is at least partly
dopamine dependent, since it diminished significantly following
reduction in dopaminergic treatment permitted by STN stimu-
lation. Only 1 of our 11 creative patients continued to main-
tain a high level of creativity 1 year after surgery. Patients who
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immerse themselves in creativity are typically convinced that their
passion is the expression of their own personality and not influ-
enced by the drugs they are taking to treat Parkinsonism. They
are attached to their creativity, since it is a source of strong
personal enrichment, an “awakening” that is socially recognized
(unless it escalates to addictive pathological behavior, as in our
case study). When surgery is envisaged by medical staff, cre-
ative patients should be warned that it could, as observed in
this study, induce a decrease in creative activity via the reduc-
tion in dopaminergic treatment. If treatment is maintained, the
cumulative effects of stimulation and dopamine agonists could
exacerbate creativity (44), and other hyperdopaminergic behav-
iors (45). The creativity–dopamine agonist therapy link and the
absence of difference between both hemisphere parameters of STN
DBS we found do not support previous work showing an acute
and lateralized direct annihilating effect of STN DBS on creativ-
ity in an isolated PD patient (46). Reduction in DRT, especially
dopamine agonists, permitted by STN DBS induces not only a
decrease in creativity, but also an overall decrease in motivated
behaviors (16) reaching severe apathy level (17). Dopaminergic
treatment seems to influence all goal-directed behaviors with a
reward component, contrary to the disease itself which leads to
loss of motivation related to mesolimbic dopaminergic denerva-
tion (17). This explains the continuum of observed behaviors in
PD with awakening of the desire to undertake pleasant activities
if the mesolimbic system is rich in dopamine, and extinction of
the desire to undertake pleasant activities if the mesolimbic system
lacks dopamine.
PSYCHOLOGICAL PROFILE OF CREATIVE PATIENTS
Creative patients are more hypomanic, more active at night; they
pursue more other hobbies and function in a more appetitive mode
than controls. They are also less apathetic and experience more
pronounced ON euphoria and less severe OFF dysphoria. This
profile corresponds to an enthusiastic and energetic personality,
with a proliferation of ideas and desires, an ease of association, a
less conventional way of thinking, good levels of self-confidence,
and belief in their capacity to accomplish great things. We suggest
that there may be a link between the high prevalence of creativity in
PD patients with a hypomanic profile and bipolar disorder which is
also associated with creativity (47). We wonder if it would be legiti-
mate to make an analogy between bipolar disorder and fluctuating
PD patients, who are subject to repeated, ultra-rapid mood cycles
parallel to motor fluctuations, in the same day. Creative patients in
our study were taking more dopamine agonists and antidepressant
and anxiolytic drugs. Could their medication actually cover up
more severe non-motor OFFs requiring higher doses and associa-
tion of medication than those of control patients? PD and bipolar
disorder both lead to over-expression of creative talent, favoring
the hypothesis that mesolimbic dopaminergic system dysfunction
is a mechanism of bipolar disorder as it is the case in PD.
Creative patients did not necessarily present more impulse con-
trol disorders or l-DOPA addiction than controls, on the contrary,
although they have higher doses of dopamine agonist. This result
is compatible with the absence of association between artistic
creativity and impulsivity or impulse control disorder observed
by Canesi et al. (48), in contrast to other work showing that
involvement in a creative or artistic profession can be a potential
risk to develop impulse control disorder in PD (49).
OTHER FACTORS EXPLAINING CREATIVITY
Given the importance of a well-functioning prefrontal cortex for
creativity exist, it is conceivable that the bilateral insertion into the
frontal lobe of microelectrodes and DBS leads has an impact on
creativity. This would count for cases as well as controls, but since
the controls were already not creative before surgery, decreased
creativity would not be evident in this group. However, our data
showed a good maintain of frontal score (superior to 40/50, which
is good) both in cases and controls after surgery.
When examining the influence of the side of the body onset of
PD, we did not find any association with creativity, on the contrary
to previous work (50).
Dopamine agonists probably facilitate creativity, but do not
generate it on their own. Non-neurobiological factors favoring
creativity in PD should also be investigated in order to advance
research in this domain. PD patients need to communicate by
unconventional means of expression in order to face up to their
pathology which is often difficult for their relatives to understand,
and socially stigmatized. Onset of PD generally occurs around
retirement age and Parkinson-related disability may also lead to
premature discontinuation of professional activity. Retirement is
usually the time to enjoy life and realize longstanding dreams of
youth. Psychodynamic models also explain creativity in PD, as
a need to sublimate the accumulation of all the large and small
frustrations of living with PD every day: inability to carry out
plans, being made fun of in public, being unable to wear the same
clothes anymore, no longer being able to perform certain dance
steps, being discouraged from driving a car. Art is the expression
of the soul and the PD patient’s soul has a lot to express.
LIMITS
Our work provides the first group study linking creativity to
dopamine agonists’ therapy in PD. However, the present study
has several methodological and conceptual limits. The sample
sizes are relatively small, and can question the generalization of
our results to PD candidates to surgery and to PD in general.
However, we present convincing statistically significant results on
this small population of selected patients to surgery. We propose
to generalize our results to PD patients without relevant exec-
utive dysfunction (as it is the case in patients selected for STN
DBS) and exposed to dopamine agonists. In spite of PD, these
patients conserve good cortico-cortical projection functioning. We
do not intend to generalize our results to cognitively impaired PD
patients, with important spread of alpha-synucleinopathy in the
different cortical areas (51). Even if exposed to dopamine agonists,
these cognitively impaired patients might not develop creativity,
because they are lacking the basis of creative acts: concept elabora-
tion, fluency, mental flexibility, i.e., intact executive function (52).
Furthermore, creativity was evaluated on a single item on a single
scale. However, no specific validated tool does exist in the context
of PD. The existing psychometric divergent thinking battery that
was used in PD, the Torrance Test of Creative Thinking did not
permit to differentiate creative PD patients from healthy controls
without creativity, which questions its validity (48).
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CONCLUSION
Creative patients have higher doses of dopamine agonists than
controls presenting the same motor severity. Creativity appears
with, or is exacerbated by, dopaminergic treatment, and decreases
when dopaminergic treatment is reduced, in the context of STN
stimulation. Dopamine agonists have a more selective affinity with
D3 dopaminergic receptors, which are more highly represented in
the mesolimbic system, than l-DOPA which has a more diffuse and
balanced action on all dopaminergic receptors. Overstimulation of
mesolimbic dopaminergic systems seems to facilitate the drive to
create in PD patients who possess a certain “creative intelligence,”
in a non-specific way, via the enhancement of all directed behav-
iors with a reward component. Dopaminergic treatment in PD
induces ultra-rapid mood cycles, with euphoric/dysphoric oscilla-
tions, constituting a favorable ground for creativity, as it is the case
in bipolar disorder. While behavioral addictions and impulse con-
trol disorders are well-known potentially devastating side effects,
creativity can generally be considered as a highly beneficial side
effect of dopamine agonists.
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